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In this issue of Microbial Cell, Koh and colleagues pre-
sent data highlighting the utility of the lysosomotropic 
compound L-leucyl-L-leucyl methyl ester (LeuLeu-OMe) 
as an anti-Trypanosoma brucei agent, adding to the 
range of compounds that either directly target lysoso-
mal enzymes or that can be used to subvert the func-
tion of the lysosome for parasite destruction. 
 
Trypanosoma brucei causes devastating diseases in hu-
mans and cattle [1]. Human African trypanosomiasis (HAT), 
caused by T. b. gambiense and T. b. rhodesiense, and the 
livestock disease Nagana, caused by T. brucei and related 
parasites, are endemic to sub-Saharan Africa, with approx-
imately 60 million people living in at risk areas [2]. Due to 
sustained control efforts over the last two decades, HAT 
cases have dropped from an estimated peak of 300-500 
thousand per year in the 1990s, to less than 10,000 report-
ed cases per year since 2009 [3]. Given this success, the 
World Health Organisation has stated that HAT should be 
eliminated as a public health problem by 2020 [4]. Howev-
er, T. brucei and the related zoonotic African trypanosomes, 
T. congolense and T. vivax, still present a significant con-
straint on agricultural development in the region. Meeting 
the HAT elimination goal in an environment of widespread 
zoonotic trypanosomiasis will likely require the develop-
ment of new chemotherapeutic interventions for both HAT 
and Nagana. The current arsenal of anti-HAT drugs is lim-
ited by disease stage and sub-species specificity, as well as 
toxicity and the need for complex administration protocols 
[5]. In addition, resistance to the anti-HAT drugs, me-
larsoprol and pentamidine, has been extensively character-
ised in clinical isolates [6], and treatment failures with the 
anti-animal trypanosomiasis drugs, diminazene aceturate 
and isometamidium chloride are also seen [7]. 
A small number of new compounds are currently under 
clinical development for the treatment of HAT, including 
orally available oxaboroles [8] and fexinidazole [9]. Work is 
also ongoing to identify specific trypanosomal drug targets, 
inspired by the array of unique features present in this 
evolutionarily divergent eukaryote, which represent attrac-
tive targets for chemotherapeutic intervention [10]. Given 
this, it is perhaps surprising that the lysosome, an organelle 
found in all eukaryotes, has emerged as a promising drug 
target. Cathepsin-L, an essential T. brucei lysosomal cyste-
ine protease [11] and its homologue in the related trypa-
nosomatid T. cruzi, the causative agent of Chagas disease, 
are the subject of intense research [12], with the aim of 
developing selective inhibitors. Several other anti-parasitic 
agents either depend on proper lysosomal function for 
their efficacy, such as the anti-HAT drug suramin [13], or 
impact its function directly, such as the anti-malarial chlo-
roquine [14]. In this edition of Microbial Cell, Koh and col-
leagues highlight the anti-trypanosomal potential of other 
lysosomotropic compounds, demonstrating the selectivity 
of LeuLeu-OMe for bloodstream form T. brucei and its like-
ly mode of killing (Koh et al., 2015). LeuLeu-OMe has pre-
viously been shown to cause lysosomal membrane perme-
abilisation (LMP) in Plasmodium falciparum, though only at 
millimolar concentrations [14]. With an EC50 of 16 µM, its 
potency against T. brucei is considerably higher (Koh et al., 
2015), although this will need to be further improved, if 
LeuLeu-OMe and related compounds are to have a future 
role in HAT chemotherapy. 
LeuLeu-OMe exhibits some toxicity against mammalian 
cells, with selectivity for cytotoxic lymphocytes [15], but 
even these cells are less sensitive to this compound than T. 
brucei (Koh et al., 2015). Treatment of HeLa cells with >300 
µM LeuLeu-OMe results in LMP and the release of cathep-
sins into the cytosol, which cleave the key apoptosis regu-
lator, Bid, leading to caspase activation and apoptosis [16]. 
The phenotypes seen in P. falciparum following LMP are 
also reminiscent of apoptosis, and include mitochondrial 
membrane depolarisation and DNA fragmentation [14]. 
Apoptosis-like features have also been reported in T. brucei 
and other protozoa [17], however the absence of the key 
regulators and the caspase executioners, and the lack of 
convincing evidence for regulation of the process have led 
others to conclude that the observed cell death should be 
described as incidental or necrotic [18]. Indeed, although 
cathepsin release following LMP can lead to apoptosis in 
metazoa [16], the data presented by Koh and colleagues 
indicate that LeuLeu-OMe mediated LMP in T. brucei caus-
es necrotic cell death, without any discernible markers of 
apoptosis (Koh et al., 2015). One or both of the parasite’s 
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cathepsins (B and L) appears to be at least partly responsi-
ble for the observed necrosis, as incubation of LeuLeu-
OMe treated cells with a broad range cathepsin inhibitor 
significantly reduces cell death (Koh et al., 2015). 
The lysosome has long been recognised as a viable tar-
get for chemotherapeutic intervention that subverts its 
function for parasite destruction. Indeed, humans are re-
sistant to infection by the non-human infectious African 
trypanosomes, such as T. congolense and T. b. brucei, due 
to serum factors that target the parasite’s lysosome. Hu-
man serum contains two trypanolytic complexes, which 
rapidly lyse non-human infectious African trypanosomes: 
trypanolytic factor (TLF) 1 is a component of high density 
lipoprotein, while TLF2 is composed primarily of IgM [19]. 
The lytic component of both complexes is apolipoprotein-
L1, which forms pores in the lysosomal membrane follow-
ing a conformational change at low pH, allowing the un-
controlled entry of chloride ions into the lysosome and its 
subsequent osmotic swelling leading to parasite lysis [20]. 
The lysosome and the endocytic system that feeds into it 
are also attractive drug targets by virtue of their funda-
mental role in surface coat recycling and antigenic varia-
tion, the process whereby T. brucei changes its variant sur-
face glycoprotein coat, enabling immune evasion [21] and 
the rapid removal of bound antibody [22]. It may be these 
features, the very high endocytic rate and a necessarily 
highly active lysosome, that render bloodstream form T. 
brucei more sensitive than human cells to LeuLeu-OMe. 
The importance of the endosomal-lysosomal system to 
T. brucei survival in the mammalian host, both as a route 
for nutrient uptake and for surface coat maintenance, un-
derpins its successful targeting by both the innate immune 
system and chemotherapy [23]. Any new compounds that 
target this area are an attractive proposition. Whether, 
LeuLeu-OMe represents a significant step forward will de-
pend on the ease with which more potent and highly selec-
tive variants can be developed. 
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